Professor Hendrik Bonnemeier
Schleswig-Holstein University Clinic, Lubeck Campus, Luebeck (Germany)
Follow
Contributor content
Presentation
Renal function worsening in factor-xa inhibitors vs phenprocoumon in patients with non-valvular atrial fibrillation and renal disease - insights from the RELOADED study
Presentation
Are there shock incidence and mortality differences in primary prevention patients regarding device type and ischemia? A NORDIC ICD sub-study.
Presentation
Comparative effcomparative effectiveness and safety of factor-xa inhibitors vs phenprocoumon in patients with non-valvular atrial fibrillation and malignant diseases, insights from the RELOADED study
Presentation
Comparative safety of factor-xa inhibitors vs phenprocoumon in patients with non-valvular atrial fibrillation and renal disease - insights from the RELOADED study
Presentation
State of the art in cardiac resynchronization therapy: how device features improve clinical outcomes
Presentation
Think about the kidneys: why does renal function matter in patients with atrial fibrillation?
Presentation
Q&A and closing - Solving the puzzle of heart failure, diabetic kidney disease and risk of stroke: let’s fit the pieces together.
Presentation
Presentation
Real-world effectiveness of stroke prevention in patients with non-valvular atrial fibrillation treated with rivaroxaban vs. phenprocoumon in germany - insights from the reload study
Presentation
